scispace - formally typeset
A

Alison Jones

Researcher at Royal Free Hospital

Publications -  46
Citations -  3864

Alison Jones is an academic researcher from Royal Free Hospital. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 24, co-authored 42 publications receiving 3394 citations. Previous affiliations of Alison Jones include University College London & University College London Hospitals NHS Foundation Trust.

Papers
More filters
Journal ArticleDOI

Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials

TL;DR: Evidence is not sufficiently robust to support clear evidence-based recommendations on different anthracycline treatment regimens, or for routine use of cardiac protective agents or liposomal formulations.
Journal ArticleDOI

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M Swain, +221 more
- 01 Apr 2020 - 
TL;DR: The end-of-study analysis of CLEOPATRA found progression-free and overall survival were significantly improved in the pertuzumab group compared with the placebo group, and the overall survival rates were also significantly improved.
Journal ArticleDOI

Chemotherapy for Breast Cancer During Pregnancy: An 18-Year Experience From Five London Teaching Hospitals

TL;DR: These data provide evidence that in terms of peripartum complications and immediate fetal outcome, chemotherapy can be safely administered to women during the second and third trimesters of pregnancy.
Journal Article

In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.

TL;DR: Letrozole is therefore a highly effective inhibitor of aromatase, causing near complete inhibition of the enzyme in peripheral tissues at the doses investigated, and the falls in estrogen levels were greater than those seen with earlier generation aromat enzyme inhibitors.